All In Biotech

Drug Trial Radar · NCT06665412

Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML

A Single-arm, Open-label, Multicenter, Investigator-led Observational Study to Evaluate the Efficacy and Safety of Dose Reduction of Radotinib as a First-line Treatment in Patients With Newly Diagnosed Chronic Phase Ph+ Chronic Myeloid Leukemia.

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

169

Actual

Start

Oct 24, 2024

Primary completion

Jul 15, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Il-Yang Pharm. Co., Ltd.Industry
Sponsor type
Industry
First posted
Oct 30, 2024

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this observational study is to learn about the efficacy and safety profile when Radotinib dose redution is performed in Ph+ CML subjects. The main efficacy is checked by MMR rate by 12 months from IP treatment.

Conditions

  • Chronic Phase Ph+ Chronic Myeloid Leukemia

Interventions

  • Radotinib HydrochlorideDrug

    200mg BID, every day up to 12months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate MMR rate up to 12months following the treatment of RadotinibTime frame: up to 12months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Keimyung University Daegu Dongsan Hospital

    Daegu, South Korea

  • Hallym University Sacred Heart Hosptial

    Anyang-si, Gyeonnggi-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.